Table 2.

Schedule of assessments

	Throughout study	Pre-data collection	Baseline					Program			Follow-up			Program end
Measures	Nov 25, 2022–Jun 16, 2023	Nov 25–Dec 23, 2022	Dec 26, 2022–Jan 23, 2023					Jan 31–Apr 20, 2023			Apr 27–Jun 16, 2023			May 1–May 12, 2023
Measures			− t₅^a	− t₄^a	− t₃	− t₂	− t₁	t₁	t₂	t₃	t₄	t₅	t₆
Eligibility screen		X
Informed consent		X
Baseline length allocation (3, 4, or 5 weeks)		X
Feasibility metrics	X
Participant interview														X
Instructor interview														X
Fidelity monitoring								X^b	X^b	X^b
Primary definitive trial outcomes			X^a	X^a	X	X	X	X	X	X	X	X	X
Secondary definitive trial outcomes			X^a	X^a	X	X	X	X	X	X	X	X	X
Sociodemographic and medical characteristics			X^a	X^a	X^a
Adverse events								X^b	X^b	X^b

Notes. ^aDepending on group allocation. ^bTracked continuously throughout the program